DEC1 negatively regulates CYP2B6 expression by binding to the CYP2B6 promoter region ascribed to IL-6-induced downregulation of CYP2B6 expression in HeLa cells

References

• Abraham J, Earl HM, Pharoah PD, Caldas C. 2006. Pharmacogenetics of cancer chemotherapy. Biochim Biophys Acta. 1766(2):168–183.
   PubMed Web of Science ®Google Scholar
• Aitken AE, Morgan ET. 2007. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos. 35(9):1687–1693.
   PubMed Web of Science ®Google Scholar
• Ataie-Kachoie P, Pourgholami MH, Richardson DR, Morris DL. 2014. Gene of the month: Interleukin 6 (IL-6). J Clin Pathol. 67(11):932–937.
   PubMed Web of Science ®Google Scholar
• Brandfellner HM, Ruparel SB, Gelfond JA, Hargreaves KM. 2013. Major blunt trauma evokes selective upregulation of oxidative enzymes in circulating leukocytes. Shock. 40(3):182–187.
   PubMed Web of Science ®Google Scholar
• Chemoradiotherapy for Cervical Cancer Meta-analysis 2010. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database System Rev. CD008285.DOI:https://doi.org/10.1200/JCO.2008.16.4368
   Google Scholar
• Conceicao T, Braga C, Rosado L, Vasconcelos MJM. 2019. A review of computational methods for cervical cells segmentation and abnormality classification. IJMS. 20(20):5114.
   Google Scholar
• Dallas S, Chattopadhyay S, Sensenhauser C, Batheja A, Singer M, Silva J. 2013. Interleukins-12 and -23 do not alter expression or activity of multiple cytochrome P450 enzymes in cryopreserved human hepatocytes. Drug Metab Dispos. 41(4):689–693.
   PubMed Web of Science ®Google Scholar
• Dickmann LJ, Patel SK, Rock DA, Wienkers LC, Slatter JG. 2011. Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metab Dispos. 39(8):1415–1422.
   PubMed Web of Science ®Google Scholar
• Doi A, Kita A, Kanda Y, Uno T, Asami K, Satoh R, Nakano K, Sugiura R. 2015. Geranylgeranyltransferase Cwg2-Rho4/Rho5 module is implicated in the Pmk1 MAP kinase-mediated cell wall integrity pathway in fission yeast. Genes Cells. 20(4):310–323.
   PubMed Web of Science ®Google Scholar
• Dutheil F, Jacob A, Dauchy S, Beaune P, Scherrmann JM, Decleves X, Loriot MA. 2010. ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders. Expert Opin Drug Metab Toxicol. 6(10):1161–1174.
   PubMed Web of Science ®Google Scholar
• Efferth T, Volm M. 2005. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther. 107(2):155–176.
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV. 2004. Moving towards individualized medicine with pharmacogenomics. Nature. 429(6990):464–468.
   PubMed Web of Science ®Google Scholar
• Fujita K, Sasaki Y. 2007. Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 8(6):554–562.
   PubMed Web of Science ®Google Scholar
• Guo Y, Xu F, Lu T, Duan Z, Zhang Z. 2012. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 38(7):904–910.
   PubMed Web of Science ®Google Scholar
• Hafner M, Rezen T, Rozman D. 2011. Regulation of hepatic cytochromes p450 by lipids and cholesterol. Curr Drug Metab. 12(2):173–185.
   PubMed Web of Science ®Google Scholar
• Harborth J, Elbashir SM, Bechert K, Tuschl T, Weber K. 2001. Identification of essential genes in cultured mammalian cells using small interfering RNAs. J Cell Sci. 114(Pt 24):4557–4565.
   PubMed Web of Science ®Google Scholar
• Inciūra A, Juozaityte E. 2004. The guidelines for diagnostics and treatment of cervical cancer. Medicina (Kaunas). 40(4):394–403.
   PubMedGoogle Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J Clin. 61(2):69–90.
   PubMed Web of Science ®Google Scholar
• Jin SE, Ha H, Seo CS, Shin HK, Jeong SJ. 2018. Expression of hepatic cytochrome P450s in rats administered with Guibi-tang, a traditional herbal formula. Pharmacogn Mag. 13(Suppl 4):S822–S7.
   PubMedGoogle Scholar
• Kim JH, Sherman ME, Curriero FC, Guengerich FP, Strickland PT, Sutter TR. 2004. Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers. Toxicol Appl Pharmacol. 199(3):210–219.
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Tabata T, Omori M, Kondo E, Hirata T, Yoshida K, Sekine M, Itakura A, Enomoto T, Ikeda T. 2019. A Japanese survey of malignant disease in pregnancy. Int J Clin Oncol. 24(3):328–333.
   PubMed Web of Science ®Google Scholar
• Kumari N, Dwarakanath BS, Das A, Bhatt AN. 2016. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour biology: the journal of the International Society for. Tumour Biol. 37(9):11553–11572.
   PubMedGoogle Scholar
• La Flamme AC, Pearce EJ. 1999. The absence of IL-6 does not affect Th2 cell development in vivo, but does lead to impaired proliferation, IL-2 receptor expression, and B cell responses. J Immunol. 162(10):5829–5837.
   PubMed Web of Science ®Google Scholar
• Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC. 2003. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res. 9:370–376.
   PubMed Web of Science ®Google Scholar
• Li S, Wu Z, Li L, Liu X. 2016. Interleukin-6 (IL-6) receptor antagonist protects against rheumatoid arthritis. Med Sci Monit. 22:2113–2118.
   PubMed Web of Science ®Google Scholar
• Liu MZ, He FZ, Zhang W. 2013. Epigenetic research progress of anti-tumor drugs. Yao Xue Xue Bao. 48(11):1629–1636.
   PubMedGoogle Scholar
• Oei AL, van Leeuwen CM, ten Cate R, Rodermond HM, Buist MR, Stalpers LJ, Crezee J, Kok HP, Medema JP, Franken NA. 2015. Hyperthermia selectively targets human papillomavirus in cervical tumors via p53-dependent apoptosis. Cancer Res. 75(23):5120–5129.
   PubMed Web of Science ®Google Scholar
• Petrucci MT, Ricciardi MR, Gregorj C, Ciapponi L, Savino R, Ciliberto G, Tafuri A. 2002. Effects of IL-6 variants in multiple myeloma: growth inhibition and induction of apoptosis in primary cells. Leuk Lymphoma. 43(12):2369–2375.
   PubMed Web of Science ®Google Scholar
• Prandota J. 2005. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology. Am J Ther. 12(3):254–261.
   PubMedGoogle Scholar
• Remington MC, Munson EL, Callister SM, Molitor ML, Christopherson JA, DeCoster DJ, Lovrich SD, Schell RF. 2001. Interleukin-6 enhances production of anti-OspC immunoglobulin G2b borreliacidal antibody. Infect Immun. 69(7):4268–4275.
   PubMed Web of Science ®Google Scholar
• Shimizu M. 2009. Individual differences of drug-metabolizing enzymes as determinants for the metabolic fate of chemicals-a study of trimethylamine and flavin-containing monooxygenase 3-. Yakugaku Zasshi. 129(11):1351–1356.
   PubMed Web of Science ®Google Scholar
• Thelen K, Dressman JB. 2009. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol. 61(5):541–558.
   PubMed Web of Science ®Google Scholar
• Wang Q, Ju X, Wang J, Fan Y, Ren M, Zhang H. 2018. Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies. Cancer Lett. 438:17–23.
   PubMed Web of Science ®Google Scholar
• Wei LH, Kuo ML, Chen CA, Cheng WF, Cheng SP, Hsieh FJ, Hsieh CY. 2001. Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. Gynecologic Oncology. 82(1):49–56.
   PubMed Web of Science ®Google Scholar
• Wilkinson GR. 1996. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm. 24(5):475–490.
   PubMedGoogle Scholar
• Zhao M, Xiaofei L, Gang C, Wei L, Jing X, Gang H, Ruini C, Rui N, Wei S, Jian Y, et al. 2012. DEC1 binding to the proximal promoter of CYP3A4 ascribes to the downregulation of CYP3A4 expression by IL-6 in primary human hepatocytes. Biochem Pharmacol. 84(5):701–711.
   PubMed Web of Science ®Google Scholar